Identification of Hyal2 as the cell-surface receptor for jaagsiekte sheep retrovirus and ovine nasal adenocarcinoma virus
- PMID: 12596899
- DOI: 10.1007/978-3-642-55638-8_7
Identification of Hyal2 as the cell-surface receptor for jaagsiekte sheep retrovirus and ovine nasal adenocarcinoma virus
Abstract
Jaagsiekte sheep retrovirus (JSRV) and ovine nasal adenocarcinoma virus (ONAV) replicate in the airway and cause epithelial cell tumors through the activity of their envelope (Env) proteins. Identification of the receptor(s) that mediate cell entry by these viruses is crucial to understanding the oncogenic activity of Env and for the development of gene therapy vectors based on these viruses that are capable of targeting airway cells. To identify the viral receptor(s) and to further study the biology of JSRV and ONAV, we developed retroviral vectors containing Moloney murine leukemia virus components and the Env proteins of JSRV or ONAV. We used a new technique involving positional cloning by phenotypic mapping in radiation hybrid cells to identify and clone the human receptor for JSRV, Hyal2, which also serves as the receptor for ONAV. Hyal2 is a glycosylphosphatidylinositol-anchored cell-surface protein that has low hyaluronidase activity and is a member of a large family that includes sperm hyaluronidase (Spam) and serum hyaluronidase (Hyal1). Hyal2 is located in a region of human chromosome 3p21.3 that is often deleted in lung cancer, suggesting that it may be a tumor suppressor. However, its role in JSRV or ONAV tumorigenesis, if any, is still unclear. JSRV vectors are capable of transducing various human cells, and are being further evaluated for gene therapy purposes.
Similar articles
-
Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)-anchored cell-surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation.Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4443-8. doi: 10.1073/pnas.071572898. Proc Natl Acad Sci U S A. 2001. PMID: 11296287 Free PMC article.
-
Improved enzootic nasal tumor virus pseudotype packaging cell lines reveal virus entry requirements in addition to the primary receptor Hyal2.J Virol. 2005 Jan;79(1):87-94. doi: 10.1128/JVI.79.1.87-94.2005. J Virol. 2005. PMID: 15596804 Free PMC article.
-
Mechanism of cell entry and transformation by enzootic nasal tumor virus.J Virol. 2002 Mar;76(5):2141-9. doi: 10.1128/jvi.76.5.2141-2149.2002. J Virol. 2002. PMID: 11836391 Free PMC article.
-
Advances in the study of transmissible respiratory tumours in small ruminants.Vet Microbiol. 2015 Dec 14;181(1-2):170-7. doi: 10.1016/j.vetmic.2015.08.008. Epub 2015 Aug 12. Vet Microbiol. 2015. PMID: 26340900 Review.
-
Hyaluronidase 2 and its intriguing role as a cell-entry receptor for oncogenic sheep retroviruses.Semin Cancer Biol. 2008 Aug;18(4):296-301. doi: 10.1016/j.semcancer.2008.03.010. Epub 2008 Mar 26. Semin Cancer Biol. 2008. PMID: 18485731 Free PMC article. Review.
Cited by
-
Fusogenicity of Jaagsiekte sheep retrovirus envelope protein is dependent on low pH and is enhanced by cytoplasmic tail truncations.J Virol. 2008 Mar;82(5):2543-54. doi: 10.1128/JVI.01852-07. Epub 2007 Dec 19. J Virol. 2008. PMID: 18094165 Free PMC article.
-
Enzootic nasal tumor virus envelope requires a very acidic pH for fusion activation and infection.J Virol. 2008 Sep;82(18):9023-34. doi: 10.1128/JVI.00648-08. Epub 2008 Jul 16. J Virol. 2008. PMID: 18632865 Free PMC article.
-
Comparison of LTR enhancer elements in sheep beta retroviruses: insights into the basis for tissue-specific expression.Virus Genes. 2007 Oct;35(2):303-12. doi: 10.1007/s11262-007-0079-y. Epub 2007 Feb 1. Virus Genes. 2007. PMID: 17268841
-
Nasal adenocarcinoma associated with jaagsiekte sheep retrovirus infection in a sheep.J Vet Diagn Invest. 2020 Jan;32(1):152-155. doi: 10.1177/1040638719897032. Epub 2019 Dec 30. J Vet Diagn Invest. 2020. PMID: 31884891 Free PMC article.
-
CS lyases: structure, activity, and applications in analysis and the treatment of diseases.Adv Pharmacol. 2006;53:187-215. doi: 10.1016/S1054-3589(05)53009-6. Adv Pharmacol. 2006. PMID: 17239767 Free PMC article. Review. No abstract available.